Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 2, 2010, Pages 331-341

  Deng, Yangmei ^a   Theken, Katherine N ^a   Lee, Craig R ^a,b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2C; CYP2J; Cytochrome P450; EET; Endothelial; Epoxyeicosatrienoic acid; Epoxygenase; Inflammation; Soluble epoxide hydrolase

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; 8,9 EPOXYICOSATRIENOIC ACID; CYCLOOXYGENASE 2; CYTOCHROME P450 2C; CYTOCHROME P450 2J2; DOCOSAHEXAENOIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ETANERCEPT; GELATINASE B; GW 96625; HEME OXYGENASE 1; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PHOSPHOLIPASE A2; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BACTERIAL PNEUMONIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CATALYSIS; CELL SURVIVAL; CORONARY ARTERY DISEASE; DRUG TARGETING; ENDOTHELIUM CELL; EPOXIDATION; GENETIC VARIABILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; LEUKOCYTE ADHERENCE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CYTOCHROME P-450 ENZYME SYSTEM; EPOXIDE HYDROLASES; HUMANS; INFLAMMATION; SOLUBILITY;

EID: 74149087263     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.10.022     Document Type: Review

References (140)

1. Brash A.R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 274 (1999) 23679-23682
2. Smith W.L., Garavito R.M., and DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271 (1996) 33157-33160
3. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82 (2002) 131-185
4. Zeldin D.C. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 276 (2001) 36059-36062
5. Rendic S., and Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29 (1997) 413-580
6. Wu S., Moomaw C.R., Tomer K.B., Falck J.R., and Zeldin D.C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 271 (1996) 3460-3468
7. Fang X., Kaduce T.L., Weintraub N.L., Harmon S., Teesch L.M., Morisseau C., et al. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J. Biol. Chem. 276 (2001) 14867-14874
8. Spector A.A., Fang X., Snyder G.D., and Weintraub N.L. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 43 (2004) 55-90
9. Enayetallah A.E., French R.A., Thibodeau M.S., and Grant D.F. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J. Histochem. Cytochem. 52 (2004) 447-454
10. Larsen B.T., Miura H., Hatoum O.A., Campbell W.B., Hammock B.D., Zeldin D.C., et al. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H491-H499
11. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999) 1276-1279
12. Campbell W.B., Gebremedhin D., Pratt P.F., and Harder D.R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78 (1996) 415-423
13. Fisslthaler B., Popp R., Kiss L., Potente M., Harder D.R., Fleming I., et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401 (1999) 493-497
14. Feletou M., and Vanhoutte P.M. Endothelium-derived hyperpolarizing factor: where are we now?. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1215-1225
15. Sinal C.J., Miyata M., Tohkin M., Nagata K., Bend J.R., and Gonzalez F.J. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J. Biol. Chem. 275 (2000) 40504-40510
16. Manhiani M., Quigley J.E., Knight S.F., Tasoobshirazi S., Moore T., Brands M.W., et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am. J. Physiol. Renal. Physiol. 297 (2009) F740-F748
17. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., and Hammock B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2002) 690-694
18. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87 (2000) 992-998
19. Monti J., Fischer J., Paskas S., Heinig M., Schulz H., Gosele C., et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat. Genet. 40 (2008) 529-537
20. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat. 82 (2007) 60-67
21. Gauthier K.M., Deeter C., Krishna U.M., Reddy Y.K., Bondlela M., Falck J.R., et al. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ. Res. 90 (2002) 1028-1036
22. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., and Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9772-9777
23. Luria A., Weldon S.M., Kabcenell A.K., Ingraham R.H., Matera D., Jiang H., et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J. Biol. Chem. 282 (2007) 2891-2898
24. Seubert J.M., Sinal C.J., Graves J., DeGraff L.M., Bradbury J.A., Lee C.R., et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 99 (2006) 442-450
25. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
26. Pritchard Jr. K.A., Tota R.R., Stemerman M.B., and Wong P.Y. 14, 15-Epoxyeicosatrienoic acid promotes endothelial cell dependent adhesion of human monocytic tumor U937 cells. Biochem. Biophys. Res. Commun. 167 (1990) 137-142
27. Fleming I., Michaelis U.R., Bredenkotter D., Fisslthaler B., Dehghani F., Brandes R.P., et al. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ. Res. 88 (2001) 44-51
28. Falck J.R., Reddy L.M., Reddy Y.K., Bondlela M., Krishna U.M., Ji Y., et al. 11,12-Epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg. Med. Chem. Lett. 13 (2003) 4011-4014
29. Liu Y., Zhang Y., Schmelzer K., Lee T.S., Fang X., Zhu Y., et al. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16747-16752
30. Moshal K.S., Zeldin D.C., Sithu S.D., Sen U., Tyagi N., Kumar M., et al. Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia. J. Cell. Physiol. 215 (2008) 771-781
31. Pratt P.F., Rosolowsky M., and Campbell W.B. Effects of epoxyeicosatrienoic acids on polymorphonuclear leukocyte function. Life Sci. 70 (2002) 2521-2533
32. de Winther M.P., Kanters E., Kraal G., and Hofker M.H. Nuclear factor kappaB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 904-914
33. Morin C., Sirois M., Echave V., Gomes M.M., and Rousseau E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. Am. J. Respir. Cell. Mol. Biol. 38 (2008) 192-201
34. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 18733-18738
35. Smith K.R., Pinkerton K.E., Watanabe T., Pedersen T.L., Ma S.J., and Hammock B.D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2186-2191
36. Feige J.N., Gelman L., Michalik L., Desvergne B., and Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid. Res. 45 (2006) 120-159
37. Plutzky J. Medicine. PPARs as therapeutic targets: reverse cardiology. Science 302 (2003) 406-407
38. Wray J., and Bishop-Bailey D. Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology. Exp. Physiol. 93 (2008) 148-154
39. Pasceri V., Wu H.D., Willerson J.T., and Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101 (2000) 235-238
40. Wang N., Verna L., Chen N.G., Chen J., Li H., Forman B.M., et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 277 (2002) 34176-34181
41. Cowart L.A., Wei S., Hsu M.H., Johnson E.F., Krishna M.U., Falck J.R., et al. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J. Biol. Chem. 277 (2002) 35105-35112
42. Fang X., Hu S., Watanabe T., Weintraub N.L., Snyder G.D., Yao J., et al. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J. Pharmacol. Exp. Ther. 314 (2005) 260-270
43. Fang X., Hu S., Xu B., Snyder G.D., Harmon S., Yao J., et al. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H55-H63
44. Ng V.Y., Huang Y., Reddy L.M., Falck J.R., Lin E.T., and Kroetz D.L. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug. Metab. Dispos. 35 (2007) 1126-1134
45. Liu Y., Zhu Y., Rannou F., Lee T.S., Formentin K., Zeng L., et al. Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation 110 (2004) 1128-1133
46. Orozco L.D., Kapturczak M.H., Barajas B., Wang X., Weinstein M.M., Wong J., et al. Heme oxygenase-1 expression in macrophages plays a beneficial role in atherosclerosis. Circ. Res. 100 (2007) 1703-1711
47. Morita T., and Kourembanas S. Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J. Clin. Invest. 96 (1995) 2676-2682
48. Sacerdoti D., Escalante B., Abraham N.G., McGiff J.C., Levere R.D., and Schwartzman M.L. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 243 (1989) 388-390
49. Sacerdoti D., Bolognesi M., Di Pascoli M., Gatta A., McGiff J.C., Schwartzman M.L., et al. Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H1999-H2002
50. Sacerdoti D., Colombrita C., Di Pascoli M., Schwartzman M.L., Bolognesi M., Falck J.R., et al. 11,12-Epoxyeicosatrienoic acid stimulates heme-oxygenase-1 in endothelial cells. Prostaglandins Other Lipid Mediat. 82 (2007) 155-161
51. Abraham N.G., Jiang S., Yang L., Zand B.A., Laniado-Schwartzman M., Marji J., et al. Adenoviral vector-mediated transfer of human heme oxygenase in rats decreases renal heme-dependent arachidonic acid epoxygenase activity. J. Pharmacol. Exp. Ther. 293 (2000) 494-500
52. Wink D.A., Osawa Y., Darbyshire J.F., Jones C.R., Eshenaur S.C., and Nims R.W. Inhibition of cytochromes P450 by nitric oxide and a nitric oxide-releasing agent. Arch. Biochem. Biophys. 300 (1993) 115-123
53. Bauersachs J., Popp R., Hecker M., Sauer E., Fleming I., and Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94 (1996) 3341-3347
54. Wang H., Lin L., Jiang J., Wang Y., Lu Z.Y., Bradbury J.A., et al. Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J. Pharmacol. Exp. Ther. 307 (2003) 753-764
55. Hercule H.C., Schunck W.H., Gross V., Seringer J., Leung F.P., Weldon S.M., et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler. Thromb. Vasc. Biol. 29 (2009) 54-60
56. Zhang L., Cui Y., Geng B., Zeng X., and Tang C. 11,12-Epoxyeicosatrienoic acid activates the l-arginine/nitric oxide pathway in human platelets. Mol. Cell. Biochem. 308 (2008) 51-56
57. Kozak W., Aronoff D.M., Boutaud O., and Kozak A. 11,12-Epoxyeicosatrienoic acid attenuates synthesis of prostaglandin E2 in rat monocytes stimulated with lipopolysaccharide. Exp. Biol. Med. (Maywood) 228 (2003) 786-794
58. Kozak W., and Fraifeld V. Non-prostaglandin eicosanoids in fever and anapyrexia. Front. Biosci. 9 (2004) 3339-3355
59. Fang X., Moore S.A., Stoll L.L., Rich G., Kaduce T.L., Weintraub N.L., et al. 14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. Am. J. Physiol. 275 (1998) H2113-2121
60. Schmelzer K.R., Inceoglu B., Kubala L., Kim I.H., Jinks S.L., Eiserich J.P., et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13646-13651
61. Inceoglu B., Jinks S.L., Ulu A., Hegedus C.M., Georgi K., Schmelzer K.R., et al. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 18901-18906
62. Oliw E.H. Metabolism of 5(6)-expoxyeicosatrienoic acid by ram seminal vesicles. Formation of novel prostaglandin E1 metabolites. Biochim. Biophys. Acta. 793 (1984) 408-415
63. Carroll M.A., Balazy M., Margiotta P., Falck J.R., and McGiff J.C. Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J. Biol. Chem. 268 (1993) 12260-12266
64. Michaelis U.R., Falck J.R., Schmidt R., Busse R., and Fleming I. Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 321-326
65. Node K., Ruan X.L., Dai J., Yang S.X., Graham L., Zeldin D.C., et al. Activation of Galphas mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J. Biol. Chem. 276 (2001) 15983-15989
66. Muldowney III J.A., Painter C.A., Sanders-Bush E., Brown N.J., and Vaughan D.E. Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid. Thromb. Haemost. 97 (2007) 263-271
67. Fitzpatrick F.A., Ennis M.D., Baze M.E., Wynalda M.A., McGee J.E., and Liggett W.F. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J. Biol. Chem. 261 (1986) 15334-15338
68. Krotz F., Riexinger T., Buerkle M.A., Nithipatikom K., Gloe T., Sohn H.Y., et al. Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 595-600
69. Seubert J.M., Zeldin D.C., Nithipatikom K., and Gross G.J. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 82 (2007) 50-59
70. Yang B., Graham L., Dikalov S., Mason R.P., Falck J.R., Liao J.K., et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol. Pharmacol. 60 (2001) 310-320
71. Dhanasekaran A., Gruenloh S.K., Buonaccorsi J.N., Zhang R., Gross G.J., Falck J.R., et al. Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H724-H735
72. Bodiga S., Zhang R., Jacobs D.E., Larsen B.T., Tampo A., Manthati V.L., et al. Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels. J. Mol. Cell. Cardiol. 46 (2009) 978-988
73. Seubert J., Yang B., Bradbury J.A., Graves J., Degraff L.M., Gabel S., et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ. Res. 95 (2004) 506-514
74. Batchu S.N., Law E., Brocks D.R., Falck J.R., and Seubert J.M. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J. Mol. Cell. Cardiol. 46 (2009) 67-74
75. Katragadda D., Batchu S.N., Cho W.J., Chaudhary K.R., Falck J.R., and Seubert J.M. Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. J. Mol. Cell. Cardiol. 46 (2009) 867-875
76. Motoki A., Merkel M.J., Packwood W.H., Cao Z., Liu L., Iliff J., et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am. J. Physiol. Heart Circ. Physiol. 295 (2008) H2128-H2134
77. Nithipatikom K., Moore J.M., Isbell M.A., Falck J.R., and Gross G.J. Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H537-H542
78. Gross G.J., Hsu A., Falck J.R., and Nithipatikom K. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J. Mol. Cell. Cardiol. 42 (2007) 687-691
79. Li N., Liu J.Y., Timofeyev V., Qiu H., Hwang S.H., Tuteja D., et al. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches. J. Mol. Cell. Cardiol. (2009) Aug 28 [Electronic publication ahead of print]. doi:10.1016/j.yjmcc.2009.08.017
80. Chaudhary K.R., Batchu S.N., Das D., Suresh M.R., Falck J.R., Graves J.P., et al. Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function. Cardiovasc. Res. 83 (2009) 362-370
81. Dorrance A.M., Rupp N., Pollock D.M., Newman J.W., Hammock B.D., and Imig J.D. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 46 (2005) 842-848
82. Zhang W., Otsuka T., Sugo N., Ardeshiri A., Alhadid Y.K., Iliff J.J., et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 39 (2008) 2073-2078
83. Fleming I., Fisslthaler B., Michaelis U.R., Kiss L., Popp R., and Busse R. The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pflugers. Arch. 442 (2001) 511-518
84. Potente M., Michaelis U.R., Fisslthaler B., Busse R., and Fleming I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J. Biol. Chem. 277 (2002) 15671-15676
85. Potente M., Fisslthaler B., Busse R., and Fleming I. 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J. Biol. Chem. 278 (2003) 29619-29625
86. Medhora M., Daniels J., Mundey K., Fisslthaler B., Busse R., Jacobs E.R., et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H215-H224
87. Michaelis U.R., Fisslthaler B., Medhora M., Harder D., Fleming I., and Busse R. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J. 17 (2003) 770-772
88. Michaelis U.R., Fisslthaler B., Barbosa-Sicard E., Falck J.R., Fleming I., and Busse R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J. Cell. Sci. 118 (2005) 5489-5498
89. Pozzi A., Macias-Perez I., Abair T., Wei S., Su Y., Zent R., et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J. Biol. Chem. 280 (2005) 27138-27146
90. Wang Y., Wei X., Xiao X., Hui R., Card J.W., Carey M.A., et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J. Pharmacol. Exp. Ther. 314 (2005) 522-532
91. Zhang B., Cao H., and Rao G.N. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis. J. Biol. Chem. 281 (2006) 905-914
92. Webler A.C., Popp R., Korff T., Michaelis U.R., Urbich C., Busse R., et al. Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1123-1129
93. Webler A.C., Michaelis U.R., Popp R., Barbosa-Sicard E., Murugan A., Falck J.R., et al. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am. J. Physiol. Cell. Physiol. 295 (2008) C1292-C1301
94. Jiang J.G., Ning Y.G., Chen C., Ma D., Liu Z.J., Yang S., et al. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 67 (2007) 6665-6674
95. Cheranov S.Y., Karpurapu M., Wang D., Zhang B., Venema R.C., and Rao G.N. An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood 111 (2008) 5581-5591
96. Dhanasekaran A., Al-Saghir R., Lopez B., Zhu D., Gutterman D.D., Jacobs E.R., et al. Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H517-H531
97. Yang S., Lin L., Chen J.X., Lee C.R., Seubert J.M., Wang Y., et al. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H142-H151
98. Chen C., Li G., Liao W., Wu J., Liu L., Ma D., et al. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J. Pharmacol. Exp. Ther. 329 (2009) 908-918
99. Medhora M., Dhanasekaran A., Gruenloh S.K., Dunn L.K., Gabrilovich M., Falck J.R., et al. Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids. Prostaglandins Other Lipid Mediat. 82 (2007) 19-29
100. Davis B.B., Thompson D.A., Howard L.L., Morisseau C., Hammock B.D., and Weiss R.H. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2222-2227
101. Sun J., Sui X., Bradbury J.A., Zeldin D.C., Conte M.S., and Liao J.K. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ. Res. 90 (2002) 1020-1027
102. Ulu A., Davis B.B., Tsai H.J., Kim I.H., Morisseau C., Inceoglu B., et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J. Cardiovasc. Pharmacol. 52 (2008) 314-323
103. Zhang L.N., Vincelette J., Cheng Y., Mehra U., Chen D., Anandan S.K., et al. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 29 (2009) 1265-1270
104. Sasaki M., Ostanin D., Elrod J.W., Oshima T., Jordan P., Itoh M., et al. TNF-alpha -induced endothelial cell adhesion molecule expression is cytochrome P-450 monooxygenase dependent. Am. J. Physiol. Cell. Physiol. 284 (2003) C422-C428
105. Granville D.J., Tashakkor B., Takeuchi C., Gustafsson A.B., Huang C., Sayen M.R., et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1321-1326
106. Fichtlscherer S., Dimmeler S., Breuer S., Busse R., Zeiher A.M., and Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 109 (2004) 178-183
107. Lee C.R., North K.E., Bray M.S., Fornage M., Seubert J.M., Newman J.W., et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum. Mol. Genet. 15 (2006) 1640-1649
108. Moghaddam M.F., Grant D.F., Cheek J.M., Greene J.F., Williamson K.C., and Hammock B.D. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat. Med. 3 (1997) 562-566
109. Slim R., Hammock B.D., Toborek M., Robertson L.W., Newman J.W., Morisseau C.H., et al. The role of methyl-linoleic acid epoxide and diol metabolites in the amplified toxicity of linoleic acid and polychlorinated biphenyls to vascular endothelial cells. Toxicol. Appl. Pharmacol. 171 (2001) 184-193
110. Barbosa-Sicard E., Markovic M., Honeck H., Christ B., Muller D.N., and Schunck W.H. Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem. Biophys. Res. Commun. 329 (2005) 1275-1281
111. Ye D., Zhang D., Oltman C., Dellsperger K., Lee H.C., and VanRollins M. Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J. Pharmacol. Exp. Ther. 303 (2002) 768-776
112. Lauterbach B., Barbosa-Sicard E., Wang M.H., Honeck H., Kargel E., Theuer J., et al. Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension 39 (2002) 609-613
113. Abdel-Razzak Z., Loyer P., Fautrel A., Gautier J.C., Corcos L., Turlin B., et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol. Pharmacol. 44 (1993) 707-715
114. Sewer M.B., Koop D.R., and Morgan E.T. Endotoxemia in rats is associated with induction of the P4504A subfamily and suppression of several other forms of cytochrome P450. Drug. Metab. Dispos. 24 (1996) 401-407
115. Barclay T.B., Peters J.M., Sewer M.B., Ferrari L., Gonzalez F.J., and Morgan E.T. Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent. J. Pharmacol. Exp. Ther. 290 (1999) 1250-1257
116. Cui X., Wu R., Zhou M., Simms H.H., and Wang P. Differential expression of cytochrome P450 isoforms in the lungs of septic animals. Crit. Care Med. 32 (2004) 1186-1191
117. Yaghi A., Bradbury J.A., Zeldin D.C., Mehta S., Bend J.R., and McCormack D.G. Pulmonary cytochrome P-450 2J4 is reduced in a rat model of acute Pseudomonas pneumonia. Am. J. Physiol. Lung Cell Mol. Physiol. 285 (2003) L1099-L1105
118. Yaghi A., Bend J.R., Webb C.D., Zeldin D.C., Weicker S., Mehta S., et al. Excess nitric oxide decreases cytochrome P-450 2J4 content and P-450-dependent arachidonic acid metabolism in lungs of rats with acute pneumonia. Am. J. Physiol. Lung Cell Mol. Physiol. 286 (2004) L1260-L1267
119. Ogungbade G.O., Akinsanmi L.A., Jiang H., and Oyekan A.O. Role of epoxyeicosatrienoic acids in renal functional response to inhibition of NO production in the rat. Am. J. Physiol. Renal. Physiol. 285 (2003) F955-F964
120. Ai D., Fu Y., Guo D., Tanaka H., Wang N., Tang C., et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 9018-9023
121. Elmarakby A.A., Quigley J.E., Pollock D.M., and Imig J.D. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 47 (2006) 557-562
122. Zhao X., Pollock D.M., Inscho E.W., Zeldin D.C., and Imig J.D. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension 41 (2003) 709-714
123. Kaergel E., Muller D.N., Honeck H., Theuer J., Shagdarsuren E., Mullally A., et al. P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 40 (2002) 273-279
124. Muller D.N., Theuer J., Shagdarsuren E., Kaergel E., Honeck H., Park J.K., et al. A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am. J. Pathol. 164 (2004) 521-532
125. Zhao X., Dey A., Romanko O.P., Stepp D.W., Wang M.H., Zhou Y., et al. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 (2005) R188-R196
126. Wang M.H., Smith A., Zhou Y., Chang H.H., Lin S., Zhao X., et al. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 42 (2003) 594-599
127. Maresh J.G., Xu H., Jiang N., Gairola C.G., and Shohet R.V. Tobacco smoke dysregulates endothelial vasoregulatory transcripts in vivo. Physiol. Genomics 21 (2005) 308-313
128. Morgan E.T. Regulation of cytochrome p450 by inflammatory mediators: why and how?. Drug Metab. Dispos. 29 (2001) 207-212
129. Morgan E.T., Goralski K.B., Piquette-Miller M., Renton K.W., Robertson G.R., Chaluvadi M.R., et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos. 36 (2008) 205-216
130. Riddick D.S., Lee C., Bhathena A., Timsit Y.E., Cheng P.Y., Morgan E.T., et al. Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals. Drug Metab. Dispos. 32 (2004) 367-375
131. Theken K.N., and Lee C.R. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. Pharmacogenomics 8 (2007) 1369-1383
132. Spiecker M., Darius H., Hankeln T., Soufi M., Sattler A.M., Schaefer J.R., et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110 (2004) 2132-2136
133. Liu P.Y., Li Y.H., Chao T.H., Wu H.L., Lin L.J., Tsai L.M., et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 195 (2007) 199-206
134. Dai D., Zeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.I., et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11 (2001) 597-607
135. Yasar U., Bennet A.M., Eliasson E., Lundgren S., Wiman B., De Faire U., et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13 (2003) 715-720
136. Lee C.R., North K.E., Bray M.S., Couper D.J., Heiss G., and Zeldin D.C. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet. Genomics 17 (2007) 349-358
137. Przybyla-Zawislak B.D., Srivastava P.K., Vazquez-Matias J., Mohrenweiser H.W., Maxwell J.E., Hammock B.D., et al. Polymorphisms in human soluble epoxide hydrolase. Mol. Pharmacol. 64 (2003) 482-490
138. Fornage M., Boerwinkle E., Doris P.A., Jacobs D., Liu K., and Wong N.D. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109 (2004) 335-339
139. Fornage M., Lee C.R., Doris P.A., Bray M.S., Heiss G., Zeldin D.C., et al. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum. Mol. Genet. 14 (2005) 2829-2837
140. Wei Q., Doris P.A., Pollizotto M.V., Boerwinkle E., Jacobs Jr. D.R., Siscovick D.S., et al. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 190 (2007) 26-34